# TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy

> **NCT07514065** · PHASE1 · RECRUITING · sponsor: **Tasly Pharmaceutical Group Co., Ltd** · enrollment: 78 (estimated)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer Patients

## Interventions

- **DRUG:** Treatment arm: TSL2109 capsules。Oral administration。

## Key facts

- **NCT ID:** NCT07514065
- **Lead sponsor:** Tasly Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-20
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07514065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07514065, "TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07514065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*